Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
83.29
+3.81 (4.79%)
Mar 31, 2026, 4:00 PM EDT - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 25 analysts that cover Kymera Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $107.72, which forecasts a 29.33% increase in the stock price over the next year. The lowest target is $52 and the highest is $140.
Price Target: $107.72 (+29.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 12 | 12 | 12 | 14 |
| Buy | 9 | 9 | 11 | 11 | 12 | 11 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 19 | 23 | 24 | 25 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $122 → $110 | Strong Buy | Initiates | $122 → $110 | +32.07% | Mar 16, 2026 |
| UBS | UBS | Strong Buy Maintains $90 → $128 | Strong Buy | Maintains | $90 → $128 | +53.68% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $110 → $120 | Strong Buy | Maintains | $110 → $120 | +44.07% | Mar 2, 2026 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $95 → $100 | Buy | Maintains | $95 → $100 | +20.06% | Mar 2, 2026 |
| BTIG | BTIG | Strong Buy Maintains $138 → $134 | Strong Buy | Maintains | $138 → $134 | +60.88% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
43.86M
from 39.21M
Increased by 11.85%
Revenue Next Year
47.27M
from 43.86M
Increased by 7.79%
EPS This Year
-3.78
from -3.69
EPS Next Year
-4.25
from -3.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 102.9M | 102.9M | |||
| Avg | 43.9M | 47.3M | |||
| Low | 9.8M | -12.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 162.5% | 134.7% | |||
| Avg | 11.8% | 7.8% | |||
| Low | -75.0% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.20 | -3.08 | |||
| Avg | -3.78 | -4.25 | |||
| Low | -4.13 | -6.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.